Discontinued — last reported Q1 '23
MFA Financial Free cash flow decreased by 210.9% to -$8.80M in Q1 2023 compared to the prior quarter. Year-over-year, this metric declined by 106.6%, from $132.61M to -$8.80M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | |
|---|---|---|---|---|---|---|---|---|
| Value | $33.26M | $5.33M | $67.42M | $132.61M | $78.54M | $135.97M | $7.93M | -$8.80M |
| QoQ Change | — | -84.0% | >999% | +96.7% | -40.8% | +73.1% | -94.2% | -210.9% |
| YoY Change | — | — | — | — | +136.2% | >999% | -88.2% | -106.6% |